


MOMENTUM IN OUR DYNAMIC PIPELINE BASED ON EMERGING DATA



Orphan drug designation

Started Ph2 for oral TAK-994 in NT1 in Q1 FY20

Partnership with Neurocrine

1. Projected approval dates depend on data read-outs; some Wave 1 target approval dates assume accelerated approval

2. Some Wave 2 assets could be accelerated into Wave 1 if they have breakthrough data

3. Approval date assumes filing on Phase 2 data


































4. Expected new addition to the clinical pipeline with FPI projected in 1H FY20



All timelines are current best estimates as of July 31, 2020 and are subject to change due to potential impact by COVID-19

For glossary of disease abbreviations please refer to appendix.



MAXIMIZING THE VALUE OF OUR APPROVED PROGRAMS

	PHASE 1 & 2	PHASE 3	FILED
 ONCOLOGY	<p>NINLARO  Proteasome inhibitor R/R MM triplet Tx (US, EU)</p> <p>ALUNBRIG  ALK inhibitor 2L ALK+NSCLC 2nd gen TKI (GL)</p> <p>ICLUSIG  BCR-ABL inhibitor TKI res. chronic phase CML (US)</p> <p>NINLARO  Proteasome inhibitor R/R MM doublet Tx (US, EU)</p>	<p>ALUNBRIG  ALK inhibitor 1L ALK+NSCLC (CN)</p> <p>Cabozantinib <i>Exelixis</i> VEGFR/RTK inhibitor 1L RCC combo w/nivolumab (JP)</p> <p>ICLUSIG  BCR-ABL inhibitor FL Ph+ ALL (US)</p> <p>NINLARO  Proteasome inhibitor Maint. ND MM no SCT (US, EU, CN)</p> <p>ALUNBRIG  ALK inhibitor 2L ALK+NSCLC H2H with alectinib (GL)</p> <p>NINLARO  Proteasome inhibitor Maint. ND MM post-SCT (US, EU)</p>	<p>NINLARO  Proteasome inhibitor Maint. ND MM no SCT (JP)</p> <p>ALUNBRIG  ALK inhibitor ALK+NSCLC (JP)</p> <p>ADCETRIS  <i>Seattle Genetics</i> CD30 ADC CTCL (CN)</p> <p>Cabozantinib  <i>Exelixis</i> VEGFR/RTK inhibitor 2L HCC (JP)</p> <p>Niraparib  <i>GlaxoSmithKline</i> PARP 1/2 inhibitor Ovarian cancer – maint. (JP)</p> <p>Niraparib  <i>GlaxoSmithKline</i> PARP 1/2 inhibitor Ovarian cancer – salvage (JP)</p>
 RARE DISEASES	<p>NATPARA PTH replacement Hypothyroidism (JP)</p>	<p>TAKHZYRO Anti-kallikrein mAb HAE pediatric (GL)</p> <p>OBIZUR  <i>Ipsen</i> FVIII replacement CHAWI (US, EU)</p> <p>VONVENDI  vWF replacement vWD Adult Prophylaxis (GL)</p> <p>TAKHZYRO Anti-kallikrein mAb HAE (JP)</p> <p>VONVENDI  vWF replacement vWD Pediatric on-demand (GL)</p> <p>ADYNOVATE Pediatric Hema (EU)</p>	<p>TAKHZYRO Anti-kallikrein mAb HAE prophylaxis (CN)</p>
 NEUROSCIENCE			<p>BUCCOLAM  GABA Allosteric Modulator Status Epilepticus (JP)</p>
 GASTRO-ENTEROLOGY	<p>ENTYVIO  α4β7 mAb Pediatric UC/CD (GL)</p>	<p>GATTEX  GLP-2R agonist Adult-SBS (JP)</p> <p>ALOFISEL  mesenchymal stem cells Perianal Fistulas in CD (US, JP)</p> <p>GATTEX  GLP-2R agonist Pediatric-SBS (JP)</p> <p>Vonoprazan PCAB Oral disintegrated tablet formulation (JP)</p> <p>ENTYVIO  α4β7 mAb GvHD Prophylaxis (EU, JP)</p> <p>ENTYVIO  α4β7 mAb SubQ CD (US, JP)</p> <p>Vonoprazan PCAB H. Pylori (CN)</p>	<p>ENTYVIO  α4β7 mAb SubQ UC (US, JP)</p> <p>Vonoprazan PCAB Reflex Esophagitis Maintenance (CN)</p> <p>Vonoprazan PCAB Duodenal ulcer (CN)</p>
 PLASMA-DERIVED THERAPIES		<p>CINRYZE PD C1 Esterase inhibitor HAE prophylaxis (JP)</p> <p>HYQVIA  <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase CIDP (US, EU)</p> <p>HYQVIA  <i>Halozyme</i> IgG 10% + Recombinant Human Hyaluronidase Pediatric PID (US)</p>	

-  Orphan Drug Designation (in any region / indication for a given asset)
-  Potential for registration enabling Ph-2 study